Ayodeji Adegunsoye, MD, PhD, MSc, highlights how the underrepresentation of minority populations in pulmonary fibrosis genetic studies hinders accurate disease risk prediction and broader clinical ...

IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for ...

The FDA granted an orphan drug designation to novel hedgehog pathway inhibitor taladegib, also known as ENV-101, for treating ...

Nerandomilast significantly reduces the decline in forced vital capacity in adults with progressive pulmonary fibrosis over 52 weeks, thereby slowing the progression of the condition.

Living with pulmonary fibrosis, columnist Ann Reynoso writes, means no more independent, spontaneous days with enough energy for everything.

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis PR Newswire BOSTON, June 5, 2025 First-in-class agent targets WISP1 in patients with IPF ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype ...

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life ...

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials; pulmonary fibrosis is a very serious disease, with a life ...

Endeavor’s lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF).

Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, reduced exercise capacity, and quality of life, and is associated with increased mortality.

SAN FRANCISCO — Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with progressive pulmonary fibrosis, according to results ...